Humira (Adalimumab)

Humira (adalimumab) is indicated for several chronic inflammatory and autoimmune disorders where modulation of tumor necrosis factor‑α is required.

• Rheumatoid arthritis – to reduce signs and symptoms and to inhibit structural joint damage.
• Psoriatic arthritis – to improve joint inflammation and skin lesions.
• Ankylosing spondylitis – to alleviate spinal pain and stiffness.
• Crohn’s disease – to induce and maintain clinical remission.
• Ulcerative colitis – to achieve remission and mucosal healing.
• Plaque psoriasis – to clear skin plaques and reduce scaling.

• Adalimumab is a fully human monoclonal antibody that selectively binds soluble and membrane‑bound tumor necrosis factor‑alpha (TNF‑α). By occupying the cytokine’s receptor‑binding site, it prevents TNF‑α from interacting with TNF receptors 1 and 2 on cell surfaces. This blockade interrupts downstream signaling pathways that drive inflammation, cell recruitment, and tissue destruction, thereby reducing the pathological immune response characteristic of autoimmune diseases.

Adalimumab may cause a range of adverse reactions, from mild to severe, that are reported in clinical use.

Common

• Injection‑site pain, redness, or swelling.
• Upper respiratory tract infections such as sinusitis or nasopharyngitis.
• Headache.
• Mild rash or pruritus.
• Nausea or abdominal discomfort.
• Fatigue.

Serious

• Serious infections, including tuberculosis and opportunistic pathogens.
• Reactivation of hepatitis B virus.
• New or worsening heart failure.
• Demyelinating disorders such as multiple sclerosis‑like events.
• Lupus‑like syndrome with joint pain and serology changes.
• Certain malignancies, notably lymphoma and skin cancers.

Before initiating therapy with Humira, several safety considerations should be evaluated to minimize risk.

• Screen for latent tuberculosis and treat before starting therapy.
• Assess for active infections; postpone treatment if infection is present.
• Evaluate history of chronic or recurrent infections, including hepatitis B or C.
• Review cardiac status, especially in patients with moderate to severe heart failure.
• Consider potential for demyelinating disease or multiple sclerosis.
• Discuss pregnancy, lactation, and contraception plans, as safety data are limited.
• Monitor for signs of malignancy during long‑term use.

Adalimumab can interact with other medicines, affecting efficacy or safety.

Avoid

• Live vaccines (e.g., measles, varicella) due to risk of infection.
• Concomitant use with other biologic immunosuppressants (e.g., abatacept, rituximab) unless specifically indicated.

Use with caution

• Systemic corticosteroids, which may increase infection risk.
• Immunosuppressive agents such as azathioprine or methotrexate.
• Antiviral therapy for hepatitis B, requiring close monitoring.
• Cyclosporine or other calcineurin inhibitors.
• Anticoagulants, as injection site bleeding may be enhanced.